Figure 1 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
<p>Patient prescreening/screening and enrollment. *One (0.3%) patient was enrolled based on local testing in a protocol violation. LBx-negative, negative for <i>MET</i>ex14 skipping in LBx; LBx-positive, positive for <i>MET</i>ex14 skipping in LBx; LBx<sub>N/A<...
Wedi'i Gadw mewn:
| Prif Awdur: | |
|---|---|
| Awduron Eraill: | , , , , , , |
| Cyhoeddwyd: |
2025
|
| Pynciau: | |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|